GYN&FORM
The computed 12-month bankruptcy probability of GYN&FORM is 0.2% (very low). The 2024 annual accounts show equity of €94k and a net result of €34k. Equity is growing by ~41.1% per year across the filed fiscal years. Its solvency ranks better than 58% of 255 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €94k |
| Net result | €34k |
| Better than sector | 58% |
| Active | 4 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 58.6% | 49.4% | |
| Net result | €34k | €50k | |
| Equity | €94k | €118k | |
| Gross operating margin | €91k | €144k | |
| Total assets | €161k | €362k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €60k |
| Net profit | €34k |
| Cash flow | €39k |
| Staff costs | - |
| Income taxes | €20k |
| Dividends | €859 |
| Total assets | €161k |
| Equity | €94k |
| Debt | €36k |
| of which ≤ 1y | €28k |
| of which > 1y | €7k |
| Working capital | €121k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 5.30 |
| Quick ratio | 5.30 |
| Working capital ratio | 75.3% |
| Solvency | 58.6% |
| Debt / equity | 0.38 |
| Long-term debt ratio | 0.08 |
| Interest coverage | 37.57 |
| Gross margin | - |
| Net margin | - |
| ROA | 21.1% |
| ROE | 36.1% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €161k |
| Fixed assets | 21/28 | €12k |
| Tangible fixed assets | 22/27 | €11k |
| Financial fixed assets | 28 | €455 |
| Current assets | 29/58 | €149k |
| Amounts receivable within one year | 40/41 | €12k |
| Investments | 50/53 | €12k |
| Cash & bank | 54/58 | €86k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €161k |
| Equity | 10/15 | €94k |
| Contributions / capital | 10/11 | €3k |
| Reserves | 13 | €92k |
| Provisions & deferred taxes | 16 | €30k |
| Amounts payable | 17/49 | €36k |
| Amounts payable after one year | 17 | €7k |
| Amounts payable within one year | 42/48 | €28k |
| Trade debts payable within one year | 44 | €1k |
| Income statement | ||
| Gross operating margin | 9900 | €91k |
| Operating result | 9901 | €55k |
| Financial income | 75 | €43 |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €54k |
| Income taxes | 67/77 | €20k |
| Net result for the period | 9904 | €34k |
| Result to be appropriated | 9905 | €34k |
| NACE primary | Human health(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 13-01-2022 |
| Status | Active |
| Postal code | 4130 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62101A0497/00A003 | Wallonia | 504 m² | 1 · 79 m² | 9.2 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
12-03-2024 2 directors appointed
- Anne AGNESSEN, Bestuurder
- SRL VERDIN & ASSOCIES, Mandataire special
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Anne AGNESSEN",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": true,
"effective_date": "2024-01-01",
"evidence_quote": "L\u0027Assembl\u00E9e g\u00E9n\u00E9rale extraordinaire du 29 janvier 2024 d\u00E9cide de nommer en tant qu\u0027administrateur, avec effet au 1er janvier 2024, Madame Anne AGNESSEN.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "mandataire_special",
"person": null,
"reason": null,
"subkind": "additional",
"via_org": {
"kbo": "0880.440.393",
"name": "SRL VERDIN \u0026 ASSOCIES",
"address": "Voie de l\u0027Ardenne n\u00B0 12 \u00E5 4053 EMBOURG",
"country": "BE",
"legal_form": "SRL"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u0027Assembl\u00E9e g\u00E9n\u00E9rale extraordinaire du 29 janvier 2024 d\u00E9signe comme mandataire sp\u00E9cial la SRL VERDIN \u0026 ASSOCIES, repr\u00E9sent\u00E9e par l\u0027un de ses administrateurs, ayant son si\u00E8ge Voie de l\u0027Ardenne n\u00B0 12 \u00E5 4053 EMBOURG, et inscrite aupr\u00E8s de la BCE n\u00B0 0880.440.393, avec pouvoir de subd\u00E9l\u00E9gation, afin de ",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2024-03-12",
"filing_date": "2024-03-05",
"act_kind_objet": "NOMINATION - POUVOIRS"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2024-01-29",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0780.434.086",
"name_full": "GYN \u0026 FORM",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Sarah PARTOUNE",
"org_rep_person_name": null,
"person_role_at_subject": "Pr\u00E9sidente"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | GYN&FORM |